
    
      This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS
      conducted in multiple centers. Drug or placebo will be given intravenously. Approximately 105
      subjects will be enrolled. Subjects will be allocated (1:1:1) to placebo and 2 dose levels of
      NP001.
    
  